浙江华海制药科技

Zhejiang Huahai Pharmaceutical Technology is a key subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd., a global leader in the production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company specializes in high-barrier generic drugs and innovative therapeutics, particularly in the cardiovascular, central nervous system (CNS), and antiviral therapeutic areas. As the first Chinese pharmaceutical company to obtain US FDA approval for finished dosage forms, Huahai maintains a robust international presence through its subsidiary Solco Healthcare. The company is increasingly focused on expanding its pipeline into biologics and oncology through its dedicated R&D platforms. Their manufacturing facilities are globally recognized for large-scale production capacity and adherence to international GMP standards.